









Markets
/
Stocks
/
nasdaq-klrs
/

Kalaris Therapeutics Inc

KLRS

5.647USD

-0.173-2.97%

Market hours （ET）Quotes delayed by 15 min

16.98MMarket Cap

LossP/E TTM



Kalaris Therapeutics Inc

5.647

-0.173-2.97%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kalaris Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Kalaris Therapeutics Inc's fundamentals are relatively very healthy, with low ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 126 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kalaris Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

126 / 391

Overall Ranking

245 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Kalaris Therapeutics Inc Highlights

StrengthsRisks

Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Undervalued

The company’s latest PE is -1.89, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 292.79K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

19.000

Target Price

+226.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Kalaris Therapeutics Inc is 5.56, ranking 345 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.56

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.82

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Kalaris Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Kalaris Therapeutics Inc is 7.55, ranking 100 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.89, which is -99.55% below the recent high of -0.01 and -58.07% above the recent low of -2.99.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 126/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Kalaris Therapeutics Inc is 8.67, ranking 72 out of 391 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 23.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

19.000

Target Price

+226.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Kalaris Therapeutics Inc

KLRS

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Kalaris Therapeutics Inc is 5.51, ranking 312 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.97 and the support level at 3.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.43

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.692

Sell

RSI(14)

22.831

Sell

STOCH(KDJ)(9,3,3)

3.516

Oversold

ATR(14)

0.724

High Vlolatility

CCI(14)

-108.640

Sell

Williams %R

96.849

Oversold

TRIX(12,20)

-1.589

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

6.005

Sell

MA10

6.827

Sell

MA20

8.184

Sell

MA50

9.029

Sell

MA100

8.159

Sell

MA200

5.924

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Kalaris Therapeutics Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 71.45%, representing a quarter-over-quarter decrease of 10.61%. The largest institutional shareholder is The Vanguard, holding a total of 292.79K shares, representing 1.28% of shares outstanding, with 107.51% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Samsara BioCapital, LLC

12.95M

+13.10%

ElevateBio LLC

724.99K

Ferrara (Napoleone)

504.00K

Invus Public Equities Advisors, LLC

318.26K

+12.63%

F2 MG Ltd

427.31K

-0.00%

The Vanguard Group, Inc.

Star Investors

203.05K

+56.39%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kalaris Therapeutics Inc is 1.85, ranking 270 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Kalaris Therapeutics Inc’s latest ESG disclosure lags behind the Biotechnology & Medical Research industry average, suggesting potential exposures in governance structure, environmental management, or social responsibility that may amplify risk and warrant ongoing monitoring.